BioSyntech Inc.
TSX VENTURE : BSY

BioSyntech Inc.

September 20, 2005 12:25 ET

BioSyntech Retains Leading Investor Relations Firm

LAVAL, CANADA--(CCNMatthews - Sept. 20, 2005) - BioSyntech, Inc. ("BioSyntech" or "the Company") (TSX VENTURE:BSY) today announced that it has retained the Equicom Group Inc. ("Equicom") to provide the Company with strategic investor relations and financial communications services.

Equicom provides strategic communications services to more than 70 Canadian public companies across a diverse range of industries. BioSyntech will pay Equicom a monthly retainer fee of $6,000 for professional services. The initial contract term is for twelve months. Neither Equicom nor any of its principals has an ownership interest, directly or indirectly, in BioSyntech or its securities, and the Company has not granted Equicom or its principals any right to acquire such an interest. The principals of Equicom are: Barry Hildred, President; Jason Hogan, Executive Vice President; Scott Kelly, Senior Vice President, Creative Services; and, Mike Polonsky, Senior Vice President.

About BioSyntech

BioSyntech is a biotechnology company specializing in the discovery, development and manufacturing of innovative cost-effective and physician-friendly therapeutic thermogels for regenerative medicine and therapeutic delivery. BioSyntech's Quality Management System is registered to ISO 9001:2000 standards. BioSyntech is listed on the TSX Venture Exchange, Canada. For additional information, visit www.biosyntech.com.

About Equicom

Headquartered in Toronto, with an office in Montreal, the Equicom Group is Canada's leading Investor Relations consulting firm. With proven expertise in developing and executing highly effective strategic communications programs, and an extensive network of investment community contacts, Equicom specializes in helping clients achieve their capital markets objectives. Equicom offers a comprehensive suite of services including: investor relations, media relations, annual report production, multimedia and web design, web casting, live event management and corporate branding. For further information, please visit www.equicomgroup.com.

NO REGULATORY AUTHORITY HAS APPROVED OR DISAPPROVED THE CONTENT OF THIS RELEASE. THE TSX VENTURE EXCHANGE DOES NOT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Contact Information

  • BioSyntech, Inc.
    Claude LeDuc
    President & CEO
    (450) 686-2437, ext. 233
    or
    The Equicom Group Inc.
    Francois Kalos
    (514) 844-6054
    fkalos@equicomgroup.com